Effect of Tamoxifen on Estrogen Receptor Levels in Breast Tumors
Author Information
Author(s): I Brotherick, DA Browell, BK Shenton, M Egan, WJ Cunliffe, LA Webb, LG Lunt, JR Young, MJ Higgs
Primary Institution: University of Newcastle upon Tyne; Queen Elizabeth Hospital, Gateshead, UK
Hypothesis
What is the effect of 3-week tamoxifen treatment on estrogen receptor levels in primary breast tumors?
Conclusion
Tamoxifen treatment for 3 weeks before surgery significantly lowers estrogen receptor levels in breast tumors compared to untreated patients.
Supporting Evidence
- ER levels were significantly lower in tamoxifen-treated patients compared to untreated patients.
- The most significant difference in receptor levels was seen in the total cell population.
- Flow cytometry was used to quantify ER levels effectively.
Takeaway
This study found that giving tamoxifen to breast cancer patients for three weeks before surgery lowers the levels of a protein that can affect cancer growth.
Methodology
Patients with breast cancer were treated with tamoxifen or received no medication, and estrogen receptor levels were measured using flow cytometry.
Limitations
The study did not compare pre- and post-tamoxifen samples from the same patient due to ethical concerns.
Participant Demographics
Patients with confirmed breast cancer, age-matched.
Statistical Information
P-Value
0.002
Confidence Interval
95% confidence interval 18 534-29 391
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website